Clinical Scorecard: Case Study: Complement Inhibitor Treatment for Bilateral Geographic Atrophy

At a Glance

Key Highlights

• Early initiation of bilateral complement inhibitor therapy can slow GA lesion growth by approximately 20% to 30% over 2 to 3 years.
• Flexible dosing intervals (every 25 to 60 days) balance treatment efficacy with patient burden and adherence.
• Sustained long-term treatment yields increasing benefit in reducing lesion growth and preserving vision-related function.

Guideline-Based Recommendations

Diagnosis

• Confirm diagnosis of dry AMD with geographic atrophy using near-infrared imaging and visual acuity assessment.
• Exclude choroidal neovascularization prior to initiating complement inhibitor therapy.

Management

• Initiate intravitreal complement inhibitor treatment early in patients with bilateral nonsubfoveal GA and good central visual acuity.
• Use staggered bilateral dosing initially to monitor for adverse effects before simultaneous bilateral injections.
• Maintain treatment every 6 to 8 weeks or individualized intervals between 25 to 60 days to ensure consistent lesion coverage.

Monitoring & Follow-up

• Regularly assess best-corrected visual acuity to monitor stability or changes.
• Perform serial imaging to evaluate GA lesion size and growth rate over time.
• Monitor for adverse effects related to intravitreal injections.

Risks

• Potential for adverse effects from intravitreal injections necessitates initial staggered dosing.
• Progression of GA lesions may continue despite treatment but at a slower rate.

Patient & Prescribing Data

Highly active elderly patients with bilateral nonsubfoveal geographic atrophy and preserved central vision.

Early bilateral treatment with flexible dosing supports maintenance of visual acuity and patient independence, aligning with patient-centered goals.

Clinical Best Practices

• Initiate complement inhibitor therapy early while central visual acuity is still strong to preserve function and independence.
• Employ staggered initiation of bilateral injections to monitor safety before simultaneous bilateral treatment.
• Utilize flexible dosing intervals tailored to patient needs to optimize adherence and balance efficacy with treatment burden.
• Commit to long-term sustained treatment to maximize reduction in GA lesion growth and maintain vision-related quality of life.

References

• FDA Approval and Clinical Trial Data on Complement Inhibitor for GA
• Long-term Clinical Trial Data on Complement Inhibitor Efficacy